Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Georgia Medicaid now covers eXciteOSA®, expanding access to innovative daytime sleep apnea therapy and reducing healthcare ...

WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

Sleep-apnoea-tackling Resmed is dreaming big but the question is: what can upset the Aussie biotech's growth story?

(HealthDay News) — For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for motor vehicle accidents (MVA) compared with continuous positive ...